New immune cell therapy shows promise for tough leukemia

NCT ID NCT05470140

Completed Disease control Sponsor: Wugen, Inc. Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 01, 2026 · Updated 26 times

Summary

This early-phase study tested a new treatment called WU-NK-101 in 9 adults with acute myeloid leukemia (AML) that had returned or not responded to standard therapy. The treatment uses specially grown natural killer cells from a donor to attack the cancer. The main goals were to check safety and find the best dose, while also looking for signs that the leukemia was shrinking.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

City of Hope

Duarte, California, 91010, United States
Norton Health Care

Louisville, Kentucky, 40299, United States
Peter MacCallum Cancer Center

Melbourne, Australia
Providence Portland Medical Center

Portland, Oregon, 97213, United States
Royal Perth Hospital

Perth, Australia
Royal Prince Alfred Hospital

Sydney, Australia
Stanford Healthcare

Palo Alto, California, 94304, United States
University of Maryland

Baltimore, Maryland, 21201, United States
Washington University

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

ACUTE MYELOID LEUKEMIA